RCOR1

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Wednesday, November 8, 2023
Research, Breast, PRMT5, NSCLC, GBM, Cancer, Pembrolizumab, Georgetown University, Safety, SITC, Preclinical development, Head, Annual general meeting, University of California, San Diego Performance-Based Skills Assessment, USP1, Biotechnology, Genta (company), Lead, University, Therapy, Patient, Society for Immunotherapy of Cancer, Neuro-oncology, MTA, SNO, Conference, RCOR1, Immunotherapy, Clinical trial, MTAP, Nervous tissue, FDA, IND, Prostate cancer, Fast Track, Pharmacokinetics, STK11, Third Rock Ventures, Drug discovery, Collaboration, Carcinoma, Jannik Madum Andersen, Glioblastoma, FTD, Mutation, PARP, Pharmaceutical industry, Vaccine, Birth control, Petroleum, Arms industry, Biology

For TNG462, we dosed the first patient in the phase 1/2 trial in July 2023.

Key Points: 
  • For TNG462, we dosed the first patient in the phase 1/2 trial in July 2023.
  • Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, November 1-5, 2023, San Diego, CA
    In November 2023, Tango scientists presented preclinical data highlighting the potential of TNG260 in STK11-mutant cancers.
  • AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 11-15, 2023, Boston, MA
    In October 2023, Tango scientists presented five posters highlighting preclinical data from the precision oncology pipeline and synthetic lethality discovery platform.
  • The year-to-date increase is the result of out-licensing a program to Gilead for $5.0 million during the second quarter of 2023.

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Monday, August 7, 2023
PK, SDMA, MTAP, CRISPR, Senior, Jannik, GBM, Repressor, MTA, Senior advisor, Clinical trial, Pharmacokinetics, Mutation, Traffic barrier, Histology, Breast, Research, NSCLC, STK11, Carcinoma, Glioblastoma, RCOR1, Animal, Jannik Madum Andersen, Patient, Drug discovery, Cancer, Neoplasm, FDA, Pembrolizumab, Collaboration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Therapy, Food, Safety, PRMT5, Pharmaceutical industry, Vaccine, Medical imaging, Management, Arms industry, Biology

BOSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the second quarter ended June 30, 2023, and provided business highlights.

Key Points: 
  • “We have significantly advanced our pipeline since the first quarter, including bringing two novel agents into phase 1/2 clinical trials.
  • Alan plans to start a new company outside of our focus, which will incubate in Tango labs, facilitating his advisor role to Tango.
  • Alan played a pivotal role founding Tango and has been an integral part of the Company from inception.
  • The increase is the result of out-licensing a program to Gilead for $5.0 million during the second quarter of 2023.

Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

Retrieved on: 
Monday, July 24, 2023
PK, Repressor, Clinical trial, Pharmacokinetics, Mutation, Breast, Fast Track, Lung cancer, Immunotherapy, STK11, Carcinoma, Development, RCOR1, Animal, Patient, Cancer, Neoplasm, Pembrolizumab, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Research

BOSTON, July 24, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG260 in combination with pembrolizumab in patients with STK11-mutant cancers.

Key Points: 
  • BOSTON, July 24, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG260 in combination with pembrolizumab in patients with STK11-mutant cancers.
  • TNG260 is a first-in-class inhibitor of the CoREST complex (Co-repressor of Repressor Element-1 Silencing Transcription).
  • “The TNG260 phase 1/2 clinical trial is the first trial to use genetic patient selection in combination with checkpoint inhibitor therapy to reverse the cancer-specific immune evasion caused by STK11 loss of function mutations.
  • Resistance to immunotherapy is a major challenge faced by patients with STK11-mutant cancers, which TNG260 is specifically designed to overcome,” said Adam Crystal, M.D., Ph.D., President of Research and Development of Tango Therapeutics.

Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, May 9, 2023
PK, SDMA, MTAP, AACR, GBM, Repressor, MTA, Bone marrow suppression, Therapeutic index, Clinical trial, Pharmacokinetics, Mutation, Traffic barrier, Histology, Fast Track, Breast, NSCLC, STK11, Carcinoma, Tango, Glioblastoma, PRMT5, Research and development, RCOR1, American Association for Cancer Research, Patient, Cancer, Annual general meeting, Neoplasm, Infrared spectroscopy correlation table, FDA, Pembrolizumab, Collaboration, Therapy, IND, FTD, Safety, Pharmaceutical industry, Vaccine, Research

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2023, and provided business highlights.

Key Points: 
  • We look forward to providing additional data from the trial in 2024,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics.
  • TNG908 proof-of-mechanism as an MTA-cooperative PRMT5 inhibitor demonstrated by marked SDMA reduction in MTAP-deleted cancer cells versus normal tissue.
  • The TNG462 Investigational New Drug (IND) application cleared in January 2023, and the first patient is expected to be dosed in mid-2023.
  • General and administrative expenses were $8.0 million for the three months ended March 31, 2023, compared to $6.8 million for the same period in 2022.

Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023
Immortalised cell line, MTAP, KRAS, AACR, Therapy, GBM, MTA, BRCA1, Therapeutic index, Clinical trial, American Association for Cancer Research, Ovary, Breast, Prostate, Publication, Lung cancer, Carcinoma, Glioblastoma, USP1, PRMT5, Non-small-cell lung cancer, Tango, Development, RCOR1, Patient, EGFR, Cancer, Annual general meeting, Mesothelioma, Escape Room, Poster, BRCA2, PD-1, Horizon, IND, PARP, Cholangiocarcinoma, Pharmaceutical industry, Vaccine, Medical imaging, Birth control, Fertilizer, STK11, Research

BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced highlights from presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.

Key Points: 
  • BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced highlights from presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.
  • “At this year’s AACR Annual Meeting, we presented preclinical data from four programs across our precision oncology portfolio, including two oral presentations.
  • It’s a tremendously exciting time for the field of precision oncology as we and others move into evaluating novel and previously not addressable targets.
  • TNG908 is 15X selective for MTAP-null cancer cells with the potential for broad clinical activity and a large therapeutic index.

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers

Retrieved on: 
Monday, April 3, 2023
Repressor, Pharmacokinetics, Mutation, Breast, NSCLC, Lung cancer, STK11, Carcinoma, RCOR1, Patient, Immune system, Cancer, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry

“FDA clearance of our IND application to initiate the TNG260 phase 1/2 trial is an important milestone in the development of this novel treatment for STK11-mutant cancers.

Key Points: 
  • “FDA clearance of our IND application to initiate the TNG260 phase 1/2 trial is an important milestone in the development of this novel treatment for STK11-mutant cancers.
  • STK11 mutations drive resistance to standard of care immunotherapy and are a major challenge in treating many cancers, including non-small cell lung cancer,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics.
  • “We expect that TNG260 will be among the first oncology molecules to leverage the benefits of genetically-based patient selection (STK11-mutation) with checkpoint inhibitor therapy.
  • The CoREST complex has been shown to play a major role in regulating the expression of immunomodulatory proteins in STK11-mutant cancers.

Beactica Therapeutics and Oscotec mutually agree to conclude oncology collaboration

Retrieved on: 
Tuesday, April 4, 2023
LSD1, GBM, Research, Glioblastoma, RCOR1, Orphan, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry

UPPSALA, Sweden and SEOUL, South Korea, April 4, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, today announced that they have mutually agreed to terminate their collaboration and licensing agreement.

Key Points: 
  • UPPSALA, Sweden and SEOUL, South Korea, April 4, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, today announced that they have mutually agreed to terminate their collaboration and licensing agreement.
  • The collaboration focused on research and development of novel anti-cancer drug candidates arising out of Beactica's LSD1 programme.
  • As part of the agreement, Beactica Therapeutics will retain full exclusive global rights for further development and commercialization of the LSD1 programme, and gain ownership of all results from the collaboration.
  • Retaining global rights to the LSD1 programme increases the potential in Beactica and is well aligned with the Company's ambition to itself become a clinical-stage company," said Dr Per Källblad, CEO of Beactica Therapeutics.

Beactica Therapeutics and Oscotec mutually agree to conclude oncology collaboration

Retrieved on: 
Tuesday, April 4, 2023
LSD1, GBM, Research, Glioblastoma, RCOR1, Orphan, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry

UPPSALA, Sweden and SEOUL, South Korea, April 4, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, today announced that they have mutually agreed to terminate their collaboration and licensing agreement.

Key Points: 
  • UPPSALA, Sweden and SEOUL, South Korea, April 4, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, today announced that they have mutually agreed to terminate their collaboration and licensing agreement.
  • The collaboration focused on research and development of novel anti-cancer drug candidates arising out of Beactica's LSD1 programme.
  • As part of the agreement, Beactica Therapeutics will retain full exclusive global rights for further development and commercialization of the LSD1 programme, and gain ownership of all results from the collaboration.
  • Retaining global rights to the LSD1 programme increases the potential in Beactica and is well aligned with the Company's ambition to itself become a clinical-stage company," said Dr Per Källblad, CEO of Beactica Therapeutics.

Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

Retrieved on: 
Monday, March 27, 2023
Abstract, MTAP, AACR, GBM, Repressor, MTA, ODD, Therapeutic index, Clinical trial, Ovary, Mutation, Traffic barrier, Breast, Prostate, Lung cancer, STK11, Carcinoma, Glioblastoma, USP1, PRMT5, Non-small-cell lung cancer, Research and development, Development, RCOR1, Investigational New Drug, American Association for Cancer Research, Patient, Immune system, Cancer, Annual general meeting, Mesothelioma, Drug discovery, BRCA, FDA, Collaboration, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, FTD, PARP, Food, Glioma, Cholangiocarcinoma, Pharmaceutical industry, Vaccine, Birth control, Cryptocurrency, BRCA1, Research

BOSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2022, and provided business highlights.

Key Points: 
  • “2022 was an important year for Tango, as we made critical strides in advancing our programs.
  • In the fourth quarter of 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to TNG908 for the treatment of malignant glioma (GBM).
  • TNG908 is an MTA-cooperative inhibitor of PRMT5 that works selectively in cancer cells with MTAP deletion.
  • MTAP deletions occur in approximately 10%-15% of all human cancers, including non-small cell lung cancer, mesothelioma, cholangiocarcinoma and GBM.

Beactica Therapeutics receives FDA Orphan Drug Designation for BEA-17 for the treatment of glioblastoma

Retrieved on: 
Wednesday, February 1, 2023
FDA, Food, Glioblastoma, Cancer, Therapy, Orphan, GBM, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LSD1, RCOR1, Patient, Entrepreneurship, Pharmaceutical industry

UPPSALA, Sweden, Feb. 1, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BEA-17 for the treatment of glioblastoma (GBM).

Key Points: 
  • UPPSALA, Sweden, Feb. 1, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BEA-17 for the treatment of glioblastoma (GBM).
  • BEA-17 is a first-in-class small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST.
  • "The designation will facilitate our development of this agent which we believe has the potential to serve as a much-needed therapeutic option for patients affected by glioblastoma."
  • The FDA's Orphan Drug Designation program supports the development of drugs that address rare diseases which affect fewer than 200,000 people in the United States.